Amgen's MariTide (maridebart cafraglutide) - a peptide that both activates GLP-1 and blocks GIP receptors, designed for once-monthly dosing - produced up to roughly 20% average weight loss at 52 weeks in a phase 2 trial in adults with obesity, with or without type 2 diabetes, results published in the New England Journal of Medicine (Jastreboff et al., 2025). Notably, weight reduction had not plateaued at 52 weeks, implying further loss with continued treatment. The novel mechanism (GLP-1 agonism plus GIP antagonism, rather than dual agonism) and monthly schedule differentiate MariTide in a crowded obesity pipeline; phase 3 MARITIME studies are now underway.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.